Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.

作者：George Sgouros, Yuni K. Dewaraja, Freddy E. Escorcia, Stephen A. Graves, Thomas A. Hope, Amir Iravani, Neeta Pandit‐Taskar, Babak Saboury, Sara St. James, Pat Zanzonico · 发表于：PubMed · 年份：2021 · DOI：10.2967/jnumed.121.262750 · 被引用次数：54 · 研究领域：Radiopharmaceutical Chemistry and Applications、Medical Imaging Techniques and Applications、Neuroendocrine Tumor Research Advances

Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT often emit photons or can be imaged using a surrogate. Such imaging may be used to estimate tumor-absorbed dose. We examine and try to elucidate those factors that impact the absorbed dose-versus-response relationship for RPT agents. These include the role of inflammation- or immune-mediated effects, the significance of theranostic imaging, radiobiology, differences in dosimetry methods, pharmacokinetic differences across patients, and the impact of tumor hypoxia on response to RPT.